PHASE 1 TRIAL OF HSVTR GENE THERAPY FOR CNS TUMORS

HSVTR 基因治疗中枢神经系统肿瘤的一期试验

• 批准号: 6244467
• 负责人: JANE B ALAVI
• 金额: $ 2.36万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-03-17 至 1998-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6244467
• 关键词: Adenoviridae; Alphaherpesvirinae; brain neoplasms; central nervous system neoplasms; clinical research; clinical trial phase I; drug delivery systems; ganciclovir; gene therapy; human subject; human therapy evaluation; neoplasm /cancer chemotherapy; neoplasm /cancer therapy; outcomes research; recombinant virus; thymidine kinase; transfection /expression vector

The purpose of this study is to determine the effectiveness and safety of a recombinant (laboratory-produced) adenovirus injected into brain tumors. The virus has been especially designed to carry a gene called herpes simplex thymidine kinase (HSV-TK). The study will investigate whether this gene (a gene is part of the nucleus of a cell) will enter brain tumor cells and make them sensitive to the killing effect of the drug ganciclovir.

这项研究的目的是确定 注射到脑肿瘤中的重组（实验室生产）腺病毒。 该病毒是专门设计用于携带一个叫做疱疹的基因的 单纯胸苷激酶（HSV-TK）。 该研究将调查是否 该基因（一个基因是细胞核的一部分）将进入脑肿瘤 细胞并使它们对药物的杀戮作用敏感 Ganciclovir。